Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
NCT06191848 on ClinicalTrials.gov · last registry update 2025-04-30
An unusually large phase 4: 352 participants, more than double the 72 typical for the stage. Due to report May 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Percentage of patients who undergo knee replacement in the target joint. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for osteoarthritis — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- University of Melbourne
- Sponsor type
- Other
- Enrollment
- 352
- Started
- 2024-11-19
- Primary completion
- 2027-05 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage of patients who undergo knee replacement in the target joint
Conditions studied
Obesity · Knee Osteoarthritis · Osteoarthritis, Knee
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.